GlassScriptPhysician profile
Laura E Popeck
NPI 1871227587
$2,517.06
in general payments reported to CMS, 2019-2025
32 companies · $861 in 2025
The $861 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $104 · 2023: $681 · 2024: $870 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,228 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,228.33 |
| Education | $184.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $342.93 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $336.21 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $244.56 | 2023-2025 | Opdivo, Opdualag |
| Seagen INC. | $157.03 | 2022-2023 | Adcetris, Tukysa |
| Astrazeneca Pharmaceuticals LP | $155.48 | 2022-2025 | Imfinzi, Enhertu, Lynparza |
| Daiichi Sankyo INC. | $117.20 | 2022-2025 | Enhertu |
| Eisai INC. | $113.76 | 2023-2024 | |
| Sobi, INC | $107.70 | 2025 | |
| Celgene Corporation | $101.74 | 2023-2024 | Reblozyl, Opdualag |
| Glaxosmithkline, LLC. | $90.77 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Astellas Pharma US INC | $80.08 | 2023-2025 | Vyloy, Padcev |
| Stemline Therapeutics INC. | $62.80 | 2023-2025 | Orserdu |
| Beigene USA, INC. | $55.34 | 2023-2024 | Brukinsa |
| Incyte Corporation | $54.30 | 2025 | Jakafi, Monjuvi |
| Regeneron Healthcare Solutions, INC. | $50.14 | 2024 | Libtayo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $49.75 | 2025 | |
| Janssen Biotech, INC. | $42.15 | 2022-2024 | Tecvayli |
| Taiho Oncology, INC. | $38.81 | 2025 | |
| Pfizer INC. | $38.30 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $35.29 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.18 | 2024 | |
| Abbvie INC. | $29.89 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.88 | 2025 | Ninlaro |
| Beone Medicines USA, INC. | $20.96 | 2025 | Brukinsa |
| Cti Biopharma Corp. | $19.18 | 2023 | Vonjo |
| Alexion Pharmaceuticals, INC. | $18.74 | 2022 | |
| Ironshore Pharmaceuticals INC. | $17.89 | 2024 | |
| Lilly USA, LLC | $16.12 | 2025 | Verzenio, Jaypirca, Retevmo |
| Amgen INC. | $15.82 | 2023 | Kyprolis, Blincyto |
| Genentech USA, INC. | $15.74 | 2022 | |
| Recordati_rare_diseases_inc. | $14.48 | 2025 | Sylvant |
| Exelixis INC. | $13.84 | 2025 | Cabometyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Popeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.